United States News Todas as matérias

HF Foods Group (NASDAQ:HFFG) announced that its Board of Directors has adopted a limited-duration stockholder rights plan, commonly known as a "poison pill," intended to protect corporate assets against potential hostile takeover attempts.

AbbVie (NYSE:ABBV) announced long-term follow-up results from its landmark Phase 3 CLL14 clinical trial, reinforcing the durable efficacy of its BCL-2 inhibitor Venclexta (venetoclax) when used as a fixed-duration therapy.

SpaceX (NASDAQ:SPCX) completed its highly anticipated transition to the public markets, staging the largest initial public offering in corporate history.

LIXTE Biotechnology (NASDAQ:LIXT) entered into a definitive agreement to acquire 100% of NOMAD Transportable Power Systems, executing a complete structural transformation away from its legacy clinical-stage oncology pipeline into a dedicated public-market platform for AI and utility energy infrastructure.

GSK (NYSE:GSK) announced that momelotinib, its approved Janus kinase (JAK) inhibitor, has received Orphan Drug Designation from both the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the treatment of VEXAS syndrome.

Oil prices fell more than 2% on Friday, extending a downswing from the previous session after U.S. President Donald Trump canceled plans for targeted military strikes against Iran.

Genmab (NASDAQ:GMAB) announced new data from a post-hoc subgroup analysis of its pivotal Phase 3 EPCORE FL-1 trial, which evaluates the subcutaneous T-cell engaging bispecific antibody epcoritamab in combination with rituximab and lenalidomide (epcoritamab plus R2).

Canaan (NASDAQ:CAN) announced its unaudited operational updates for May 2026, highlighting significant advancements in energy efficiency and geographic infrastructure expansions.

C4 Therapeutics (NASDAQ:CCCC) reported updated clinical data from its Phase 1 trial evaluating cemsidomide, an investigational oral molecular glue degrader targeting IKZF1/3, for the treatment of relapsed or refractory multiple myeloma.

Purple Biotech (NASDAQ:PPBT) unveiled new preclinical data for IM1240, its lead T-cell engager candidate utilizing the proprietary CAPTN-3 platform, at the European Association for Cancer Research (EACR) 2026 Congress.

Climb Bio (NASDAQ:CLYM) reported positive initial Phase 1b clinical data for its drug candidate budoprutug, an anti-CD19 monoclonal antibody, which is being developed to treat adults with primary immune thrombocytopenia.

Vera Bradley (NASDAQ:VRA) reported an unexpected rise in profit margins and its first quarterly top-line expansion in over four years, signaling that its comprehensive brand overhaul is beginning to resonate with retail consumers.

Syndax Pharmaceuticals (NASDAQ:SNDX) unveiled a broad array of clinical data reinforcing the therapeutic profile of its approved blood cancer drug, Revuforj, across several distinct mutations and stages of acute leukemia.

Silence Therapeutics (NASDAQ:SLN) reported positive follow-up and quality-of-life clinical data for its experimental blood cancer treatment, divesiran, demonstrating a sustained reduction in the medical procedures required to manage the rare disease.

Driven Brands Holdings (NASDAQ:DRVN) reported a rise in profit and revenue for the first quarter of fiscal 2026, supported by robust performance in its quick-lube business even as the company navigates elevated corporate expenses stemming from its recent financial restatements.

Nurix Therapeutics (NASDAQ:NRIX) released updated Phase 1a/b clinical data for its experimental leukemia drug, bexobrutideg, demonstrating sustained efficacy and high response rates across multiple lines of therapy for patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).

The Lovesac Company (NASDAQ:LOVE) reported a net loss for its fiscal 2027 first quarter, reflecting the persistent operational difficulties home furnishings retailers face as sticky inflation and elevated mortgage rates suppress discretionary consumer spending.

Takeda Pharmaceutical (NYSE:TAK) reported positive topline results from a head-to-head Phase 3 clinical trial for its experimental plaque psoriasis drug, zasocitinib, positioning the oral pill to challenge established autoimmune blockbusters.

Merck Animal Health, a subsidiary of pharmaceutical giant Merck & Co (NYSE:MRK), signed a definitive agreement to acquire TARGAN, a privately held agtech developer specializing in high-speed automated biodevices for commercial hatcheries.

Parsons (NYSE:PSN) has secured a $22 million contract amendment from the Los Angeles County Metropolitan Transportation Authority to expand infrastructure and transit enhancements along the Interstate 605 corridor.

The board of directors of Target (NYSE:TGT) declared a quarterly cash dividend of $1.16 per common share, representing a 1.8% increase over its previous distribution baseline.

Dana Incorporated (NYSE:DAN) has reached a definitive agreement to combine with Eaton's (NYSE:ETN) Mobility business, a blockbuster industrial carve-out that values the division at $5.1 billion and establishes a premier global vehicle powertrain supplier.

Copley Acquisition (NYSE:COPL) and Ignite Proteomics entered into a definitive business combination agreement that will take the biotech firm public at a pro forma enterprise value of $150 million.

Modiv Industrial (NYSE:MDV) announced the declaration of its scheduled cash distributions for both preferred and common shareholders, maintaining capital returns as the real estate investment trust prepares for its upcoming corporate combination.